Respiratory Disorders Clinical Trial
Official title:
A Two-part, Randomised, Placebo-controlled Study to Investigatethe Safety, Tolerability, Pharmacokinetics and Pharmacodynamicsof Single Doses of Inhaled GSK1995057 in Healthy Subjects
Verified date | June 2019 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
GSK1995057 is a fully human, single domain antibody directed against the TNFR1 receptor. The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of inhaled GSK1995057 in healthy subjects. The study will be in two parts. Part 1 is a single-dose escalating design of 5 sequential cohorts of healthy subjects. Part 2 is a single-dose, parallel group design comprising 2 groups of healthy subjects assessing the effect of GSK1995057 on lung inflammation following inhaled LPS challenge. Actual dose administered in Part 2 will be determined from emerging safety and PK data from Part 1 and Study TFR110951.
Status | Completed |
Enrollment | 53 |
Est. completion date | November 19, 2012 |
Est. primary completion date | November 19, 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests nd cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator considers that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. The investigator may discuss with GSK medical monitor as required. - Male or female between 18 and 55 years of age inclusive: A female subject is eligible to participate if she is of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhoea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) greater than 40 MlU/ml and oestradiol less than 40 pg/ml (less than 140 pmol/L) is confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method. Male subjects must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until the last follow-up visit. - Normal creatinine clearance values at screening (calculated from serum creatinine by a predicting equation using Cockcroft-Gault formula), normal serum creatinine value as defined by the local reference laboratory, normal urine microscopy and no significant proteinuria on dipstick testing. - Body weight greater than and equal to 50 kg and BMI within the range 19 - 29.9 kg/m2 (inclusive). - No evidence of previous or active TB infection and a negative QuantiFERON TB Gold test taken within 7 days of dosing, and negative medical history with respect to active or latent mycobacterium tuberculosis complex infection. - Normal spirometry (FEV1 greater than and equal to 85% of predicted, FEV1/FVC ratio greater than and equal to 70%) at screening. Predictions should be according to ECCS equations, and race corrections should be made for non-caucasians. - Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. - Available to complete all study assessments. - Subjects who are able to use the inhaler device correctly. - Able to read, comprehend and write English at a sufficient level to complete study related materials. Exclusion Criteria: - A history of Hepatitis B, Hepatitis C or HIV infection and/or a positive pre-study HIV, Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening - Current or chronic history of liver disease, or known hepatic or biliary abnormalities. (With the exception of known Gilbert's syndrome or asymptomatic gallstones). - A positive pre-study drug/alcohol screen. - History of and/or a positive test for toxoplasmosis consistent with active toxoplasmosis infection at the time of enrollment. - A positive RT-PCR test for influenza A/B. - Current evidence or history of an influenza-like illness as defined by fever (greater than 380C) and two or more of the following symptoms within the last 7 days: cough, sore throat, runny nose, sneezing, limb/joint pain, headache, vomiting/diarrhoea in the absence of a known cause, other than influenza. - Corrected QT interval (QTc) >450msec. - History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of greater than 21 units for males or greater than 14 units for females. One unit is equivalent to 8 g of alcohol and the following can be used as a guide: a half-pint (approximately 240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits. - The subject is unwilling to abstain from alcohol consumption from 24 hr prior to dosing until discharge from the clinic, and for 24 hr prior to all other out-patient clinic visits. - Subjects with a smoking history of greater than 5 cigarettes per day in the last 3 months (Part 1); smokers are not eligible to take part in Part 2. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | GSK Investigational Site | Belfast | |
United Kingdom | GSK Investigational Site | Harrow |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
United Kingdom,
Proudfoot AG, O'Kane CM, Bayliffe A, Serone AP, Bareille P, Smith SP, Brown V, Wright TJ, Chen Y, Wilson R, Cordy JC, Morley PJ, Elborn S, Hind M, Chilvers ER, Griffiths MJ, Summers C, McAuley DF . A novel TNFR1-targeting domain antibody attenuates pulmonary inflammation in a human model of lung injury, via actions on the lung micro-vascular endothelium.. American Journal of Respiratory and Critical Care Medicine. 2014;189:A6589
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and tolerability of ascending single inhaled doses of GSK1995057 | Adverse event reporting, Laboratory safety data (clinical chemistry, hematology, urinalysis), Vital signs (blood pressure, heart rate, respiration rate, body temperature), ECG monitoring, Spirometry monitoring (FEV1, FVC) | 56 Days | |
Primary | Levels and specificity of anti-GSK1995057 binding antibodies. | Presence of anti GSK1995057 binding antibodies. Where binding antibodies aredetected, levels and specificity of the antibodies will be evaluated | Up to 84 Days | |
Primary | Plasma pharmacokinetics of ascending single inhaled doses of GSK1995057 | Plasma concentrations of GSK1995057 and derived pharmacokinetic parameters in normal healthy subjects following single administration (all except Cohort 5). | 3 days | |
Primary | Urine pharmacokinetics of single inhaled doses of GSK1995057 | Urine concentrations of GSK1995057 and derived pharmacokinetic parameters in normal healthy subjects following a single administration (Part 1, except Cohort 5). | 3 Days | |
Primary | Concentration of GSK1995057 in lung epithelial lining fluid after inhalation of a single dose | Bronchoalveolar lavage (BAL) concentrations of GSK1995057 and derived lung deposition parameters in normal healthy subjects following a single administration (Cohorts 5 & 6 only). Bronchoalveolar lavage (BAL) concentrations of urea (Cohorts 5 & 6 only). | 1 Day | |
Primary | Effect of single inhaled doses of GSK1995057 on biomarkers | Pharmacodynamic and immune function biomarkers in serum (these may include but are not limited to sTNFR1 (free and total) and IL-6) (all except Cohort 5). | 3 Days | |
Primary | Effect of single inhaled doses of GSK1995057 on biomarkers in BAL | Bronchoalveolar lavage (BAL) neutrophil counts at 6 h post LPS exposure (Cohort 5). Other pharmacodynamic and immune function biomarkers in BAL (these may include but are not limited to TNFa and IL-6) (Cohort 5). | 1 Day | |
Primary | To explore the GSK1995057 PK-PD relationship | Pharmacodynamic and immune function biomarkers in serum and BALF (these may include but are not limited to sTNFR1 (free and total) and IL-6). Bronchoalveolar lavage (BAL) concentrations of GSK1995057 and derived lung deposition parameters in normal healthy subjects following a single administration (Cohort 5 and 6 only). Bronchoalveolar lavage (BAL) concentrations of urea (Cohorts 5 and 6 only). Change from baseline in IL-8 expression in ex vivo whole blood assay (WBA). | 1 Day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01443845 -
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
|
Phase 4 | |
Withdrawn |
NCT00844935 -
Electrocardiographic Autonomic Function Measures in Mechanically Ventilated Patients
|
N/A | |
Completed |
NCT01395849 -
Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)
|
N/A | |
Completed |
NCT03557645 -
Ventilator Hyperinflation and Hemodynamics
|
N/A | |
Completed |
NCT03281876 -
A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.
|
Phase 2 | |
Completed |
NCT01395862 -
Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)
|
N/A | |
Completed |
NCT01476046 -
Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects.
|
Phase 1 | |
Completed |
NCT00835003 -
Timing of Planned Caesarean Section and Morbidity of the Newborn
|
N/A | |
Completed |
NCT03443427 -
A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine
|
Phase 2 | |
Completed |
NCT01360398 -
Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
|
N/A | |
Completed |
NCT03201211 -
A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults
|
Phase 1 | |
Completed |
NCT02075541 -
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.
|
Phase 2 | |
Completed |
NCT00455767 -
Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients
|
Phase 2 | |
Withdrawn |
NCT01505556 -
Proprioceptive Postural Control and Diaphragm Paresis
|
||
Completed |
NCT01505582 -
Inspiratory Muscle Training and Low Back Pain
|
N/A | |
Completed |
NCT02322671 -
Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT01818024 -
A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT02316379 -
Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration
|
Phase 1/Phase 2 | |
Completed |
NCT01516437 -
A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable COPD
|
N/A | |
Recruiting |
NCT02272049 -
Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults
|
Phase 1/Phase 2 |